Atif Iqbal, MD
Colon & Rectal Surgery · Houston, TXNPI 1841398138
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,200 of the $3,638 with a category attached, or 60.5%. 6 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 51.5% of the total. Reporting peaked in 2021 at $1,875 and has fallen 98.9% since, to $20 in 2025. That places this record below the midpoint for colon & rectal surgery clinicians in TX, where the typical reported total is $4,072.
Across 13 payments — averaging $279.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Intuitive Surgical$1K
- Covidien LP$325
- Johnson & Johnson$125
- Axonics, Inc.$37
- Merck$16
Across 1 payment — averaging $151,003 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$151K
What the payments were for
- Consulting fees$2,20060%
- Food & beverage$42212%
- Education$1,01628%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,875 |
| Intuitive Surgical | 7 | $1,260 |
| Covidien LP | 1 | $325 |
| Johnson & Johnson | 1 | $125 |
| Axonics, Inc. | 2 | $37 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,638 in reported general payments places this provider in the 45th percentile of 200 colon & rectal surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Houston
- Diego Marines CopadoHouston$462K
- Erik AskenasyHouston$142K
- Eric HaasHouston$140K
- Theodoros VoloyiannisHouston$100K
- Scott McKnightHouston$73K
- Tsuyoshi KonishiHouston$68K
- Jean-Paul LefaveHouston$47K
- George ChangHouston$31K
- Michael SnyderHouston$24K
- Marianne CusickHouston$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.